Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Mutations in ZAS may be associated with congenital myopathy

May 24, 2016

Bone Therapeutics reports results from phase I/II trial of ALLOB

May 18, 2016

Ampio Pharmaceuticals begins Ampion phase I trial dosing

May 13, 2016

PABPN1 gene knockdown plus restoration partially restores muscle function in OPMD mice

May 13, 2016

Pfenex announces topline bioequivalence data for PF-708

May 10, 2016

Vitaeris obtains rights to Alder BioPharmaceuticals' clazakizumab

May 10, 2016

Cumberland Pharmaceuticals commences new systemic sclerosis program for ifetroban

April 28, 2016

FDA grants orphan drug designation to Fibrocell Science's FCX-013

April 27, 2016

Protalex reports early results from phase I/II PRTX-100 study in RA

April 26, 2016

Positive interim data from phase II trial of KRN-23 as treatment of tumor-induced osteomalacia

April 22, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...